FeesSafety
Pluang+

Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Market News
22 Nov 2026, 20:03 WIB
The Motley Fool
View Source
Bullish
Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly remains a leader in the obesity drug market with its approved products Zepbound and Foundayo showing strong sales growth. New pipeline candidates like retatrutide and EloraTZP have demonstrated greater weight loss in trials, positioning the company to maintain or grow its market share. Despite potential internal competition among its drugs, Eli Lilly's expanding portfolio and innovative treatments support continued revenue and earnings growth, justifying a premium valuation. The company is expected to sustain 20-25% EPS growth over the next five years, bolstered by progress in other therapeutic areas.

Eli Lilly's stock price on Pluang is USD 1,347.11 as of Nov 23, 2026 01:21 WIB, showing a slight decline of 0.30% in one day. The company holds a substantial market cap of $1.20 trillion, reflecting its strong position in the health sector. Investors typically hold Eli Lilly shares for about 95 days on Pluang, indicating moderate-term interest in the stock.

More News (LLY)

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly has seen its revenue soar thanks to its dominance in the weight loss drug market, with products like Mounjaro and Zepbound contributing to a 39% revenue increase to over $24 billion recently. The company leads in GLP-1 drugs, which regulate...

Market News
Bullish
14 hours ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
1 day ago
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-dr...

Market News
Bullish
1 day ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead...

Company Fundamentals
Bullish
1 day ago
AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid reve...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App